916 related articles for article (PubMed ID: 15189492)
1. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
[TBL] [Abstract][Full Text] [Related]
2. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
[TBL] [Abstract][Full Text] [Related]
3. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
5. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
6. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
7. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
8. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes.
Cnop M; Vidal J; Hull RL; Utzschneider KM; Carr DB; Schraw T; Scherer PE; Boyko EJ; Fujimoto WY; Kahn SE
Diabetes Care; 2007 Mar; 30(3):677-82. PubMed ID: 17327340
[TBL] [Abstract][Full Text] [Related]
9. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
10. Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus.
Guerrero-Romero F; Rodríguez-Morán M
Eur J Clin Invest; 2006 Nov; 36(11):796-802. PubMed ID: 17032347
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of humoral and metabolic markers as an evaluation of risk for developing type 1 diabetes].
Młynarski W; Wyka K; Bodalska-ŁIpińska J; Andrzejewski W; Zmysłowska A; Bodalski J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2003; 9(1):17-22. PubMed ID: 12831633
[TBL] [Abstract][Full Text] [Related]
12. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
13. Circadian variations in plasma immunoreactive insulin (IRI) and C-peptide concentrations in adult onset (type II) diabetes mellitus.
Nicolau GY; Haus E; Lakatua DJ; Bogdan C; Petrescu E; Sackett-Lundeen L; Stelea S; Stelea P
Endocrinologie; 1984; 22(1):3-16. PubMed ID: 6369501
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies.
Pietropaolo M; Yu S; Libman IM; Pietropaolo SL; Riley K; LaPorte RE; Drash AL; Mazumdar S; Trucco M; Becker DJ
Pediatr Diabetes; 2005 Dec; 6(4):184-92. PubMed ID: 16390386
[TBL] [Abstract][Full Text] [Related]
15. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
16. First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes.
Keskinen P; Korhonen S; Kupila A; Veijola R; Erkkilä S; Savolainen H; Arvilommi P; Simell T; Ilonen J; Knip M; Simell O
Diabetologia; 2002 Dec; 45(12):1639-48. PubMed ID: 12488953
[TBL] [Abstract][Full Text] [Related]
17. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
18. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study.
Pozzilli P; Manfrini S; Buzzetti R; Lampeter E; Leeuw ID; Iafusco D; Prisco M; Ionescu-Tirgoviste C; Kolouskovà S; Linn T; Ludvigsson J; Madàcsy L; Mrozikiewicz AS; Mrozikiewicz PM; Podar T; Vavrinec J; Vialettes B; Visalli N; Yilmaz T; Browne PD;
Diabetes Res Clin Pract; 2005 Jun; 68(3):258-64. PubMed ID: 15936469
[TBL] [Abstract][Full Text] [Related]
19. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
[TBL] [Abstract][Full Text] [Related]
20. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.
Mahon JL; Sosenko JM; Rafkin-Mervis L; Krause-Steinrauf H; Lachin JM; Thompson C; Bingley PJ; Bonifacio E; Palmer JP; Eisenbarth GS; Wolfsdorf J; Skyler JS; ;
Pediatr Diabetes; 2009 Apr; 10(2):97-104. PubMed ID: 18823409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
